[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100529662":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":36,"responsibleParty":64,"collaborators":67,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":30,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":98,"overallStatus":39,"whyStopped":30,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Baylor College of Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Phase","EXPERIMENTAL","Four dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells.\n\nCohorts of three patients will be enrolled at each dose level The dose is based on the number of CD.30 CAR-EBVT-expressing cells administered.\n\nThe total number of dose levels evaluated will depend upon toxicities experienced. Dose level cohorts will be numbered sequentially.\n\n* Dose Level 1: 4 × 10\\^7 C7R.CD30.CAR-EBVST cells\n* Dose Level 2: 1 × 10\\^8 C7R.CD30.CAR-EBVST cells\n* Dose Level 3: 4 × 10\\^8 C7R.CD30.CAR-EBVST cells\n* Dose Level 4: 8 × 10\\^8 C7R.CD30.CAR-EBVST cells",[13],"Biological: C7R.CD30.CAR-EBVST cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","C7R.CD30.CAR-EBVST cells","The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\\^8 cells\u002Fm2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.",[9],[21],"Allogeneic CR7.CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes",[23],{"name":24,"affiliation":5,"role":25},"Premal Lulla, MD","PRINCIPAL_INVESTIGATOR",[27,32],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","713-441-1450",null,"lulla@bcm.edu",{"name":33,"role":28,"phone":34,"phoneExt":30,"email":35},"Vicky Torrano, RN","(832) 824-7821","vtorrano@bcm.edu",[37,55],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Houston Methodist Hospital","RECRUITING","Houston","Texas","77030","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-95.36327,29.76328,{"lat":49,"lon":48},[52,53],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":33,"role":28,"phone":54,"phoneExt":30,"email":35},"832-824-7821",{"facility":56,"status":57,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":58,"geoPoint":60,"contacts":61},"Texas Children's Hospital","NOT_YET_RECRUITING",{"type":46,"coordinates":59},[48,49],{"lat":49,"lon":48},[62,63],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},{"name":33,"role":28,"phone":54,"phoneExt":30,"email":35},{"type":25,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Premal Lulla","Associate Professor",[68,70],{"name":69,"class":6},"The Methodist Hospital Research Institute",{"name":71,"class":6},"Center for Cell and Gene Therapy, Baylor College of Medicine","100529662","phase-1-constitutive-il7r-c7r-modified-banked-allogeneic-cd30car-ebvsts-for-cd30-positive-lymphomas-100529662",false,"NCT06176690","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas","Constitutive IL7R (C7R) Modified Banked Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas","CABAL2","Inclusion Criteria:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. CD30+ aggressive B-cell lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T- cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin less than or equal to 2 times the upper limit of normal (except for Gilbert syndrome, where the criteria will be Bilirubin less than or equal to 3 times the upper limit of normal).\n5. AST less than 3 times the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. Karnofsky or Lansky score of \\> 60%.\n9. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n10. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n11. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\n\nExclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n4. History of hypersensitivity reactions to murine protein-containing products.\n5. Pregnant or lactating.\n6. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n7. Current use of systemic corticosteroids at a dose equivalent to or higher than 10 mg\u002Fday of prednisone.\n8. Active significant, uncontrolled bacterial, viral or fungal infection.\n9. Symptomatic cardiac disease (NYHA Class III or IV disease).","ALL","12 Years","75 Years",{"count":84,"type":85},90,"ESTIMATED","INTERVENTIONAL",[88],"PHASE1","This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer\u002FT-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to collectively as lymphoma) whose disease has returned or not responded to treatment.\n\nPrevious research combined antibodies and T cells to treat cancer. Antibodies bind to foreign substances, and T cells are infection-fighting white blood cells that can kill tumor cells. Both approaches have shown promise but have not been sufficient to cure most patients. In prior studies, an antibody targeting CD30, a protein found on some T cells and cancer cells, was joined to T cells through gene transfer to create CD30.CAR T cells.\n\nAnother study showed encouraging responses using CD30.CAR T cells made from a patient's own blood and returned to the same patient (autologous cells). In an ongoing study, patients have been treated with CD30.CAR T cells derived from healthy donors (allogeneic cells), allowing use of banked cells without individualized manufacturing. This approach has shown promising clinical activity with no safety concerns to date.\n\nIn this study, investigators are evaluating CD30.CAR-EBVST cells modified with an additional molecule called C7R, which has been shown in laboratory studies to enhance anti-cancer effects. The study aims to assess the safety and effectiveness of these allogeneic, banked C7R-modified CD30.CAR-EBVST cells and determine whether they may help treat lymphoma.\n\nAs an added safety measure, the modified T cells include a marker called iC9. If significant side effects occur, patients may receive rimiducid, which can eliminate the infused T cells. Rimiducid is not yet FDA approved but has been tested in patients without significant side effects.",[91,92,93,94,95,96,97],"CD30-Positive Diffuse Large B-Cell Lymphoma","Anaplastic Large Cell Lymphoma, T Cell and Null Cell Type","Anaplastic Large Cell Lymphoma, ALK-Positive","Peripheral T-cell Lymphoma","Anaplastic Large Cell Lymphoma, ALK-negative","Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[99,100,101,102],"CD30-Positive Lymphoma","Hodgkin lymphoma","non-Hodgkin lymphoma","CD30 CAR","2026-04-07",{"date":105,"type":106},"2026-04-13","ACTUAL",{"date":108,"type":106},"2025-10-27",{"date":110,"type":85},"2043-06-27",{"name":5,"class":6},2]